Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1978 Jun;13(6):958–964. doi: 10.1128/aac.13.6.958

Infection in Acute Leukemia Patients Receiving Oral Nonabsorbable Antibiotics

Davis M Hahn 1, Stephen C Schimpff 1, Clarence L Fortner 1, A Collier Smyth 1, Viola Mae Young 1, Peter H Wiernik 1
PMCID: PMC352370  PMID: 98107

Abstract

During a 20-month period all acute nonlymphocytic patients (87 patient trials) receiving cytotoxic chemotherapy were placed on an oral nonabsorbable antibiotic regimen consisting of gentamicin, vancomycin, and nystatin in addition to an intensive program of infection prevention aimed at reducing exogenously acquired and body-surface potential pathogens. Although side effects of anorexia, diarrhea, and nausea were common, gentamicin-vancomycin-nystatin was ingested 80% of the study time. Microbial growth in gingival and rectal cultures was substantially reduced. The incidence of bacteremias and other serious infections was low. Pseudomonas aeruginosa, other gram-negative bacilli, and Candida species caused few infections along the alimentary canal, whereas infections of the skin (especially Staphylococcus aureus) were not reduced compared with those occurring in former years. A total of the 104 acquired gram-negative bacilli were gentamicin resistant; 5 subsequently caused infection. Thus, despite certain definite drawbacks, the use of oral nonabsorbable antibiotics to suppress alimentary tract microbial flora in combination with other infection prevention techniques in granulocytopenic cancer patients has proven feasible and tolerable and has been associated with a low order of life-threatening infections.

Full text

PDF
958

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aisner J., Schimpff S. C., Bennett J. E., Young V. M., Wiernik P. H. Aspergillus infections in cancer patients. Association with fireproofing materials in a new hospital. JAMA. 1976 Jan 26;235(4):411–412. [PubMed] [Google Scholar]
  2. Bauer A. W., Kirby W. M., Sherris J. C., Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966 Apr;45(4):493–496. [PubMed] [Google Scholar]
  3. Bodey G. P., Gehan E. A., Freireich E. J., Frei E., 3rd Protected environment-prophylactic antibiotic program in the chemotherapy of acute leukemia. Am J Med Sci. 1971 Sep;262(3):138–151. doi: 10.1097/00000441-197109000-00001. [DOI] [PubMed] [Google Scholar]
  4. Bodey G. P. Infections in cancer patients. Cancer Treat Rev. 1975 Jun;2(2):89–128. doi: 10.1016/s0305-7372(75)80005-3. [DOI] [PubMed] [Google Scholar]
  5. Bodey G. P., Rosenbaum B. Effect of prophylactic measures on the microbial flora of patients in protected environment units. Medicine (Baltimore) 1974 May;53(3):209–228. doi: 10.1097/00005792-197405000-00004. [DOI] [PubMed] [Google Scholar]
  6. Dietrich M., Gaus W., Vossen J., van der Waaij D., Wendt F. Protective isolation and antimicrobial decontamination in patients with high susceptibility to infection. A prospective cooperative study of gnotobiotic care in acute leukemia patients. I: clinical results. Infection. 1977;5(2):107–114. doi: 10.1007/BF01642091. [DOI] [PubMed] [Google Scholar]
  7. Dietrich M., Rasche H., Rommel K., Hochapfel G. Antimicrobial therapy as a part of the decontamination procedures for patients with acute leukemia. Eur J Cancer. 1973 Jun;9(6):443–447. doi: 10.1016/0014-2964(73)90109-6. [DOI] [PubMed] [Google Scholar]
  8. Greene W. H., Moody M., Schimpff S., Young V. M., Wiernik P. H. Pseudomonas aeruginosa resistant to carbenicillin and gentamicin. Epidemiologic and clinical aspects in a cancer center. Ann Intern Med. 1973 Nov;79(5):684–689. doi: 10.7326/0003-4819-79-5-684. [DOI] [PubMed] [Google Scholar]
  9. HERSH E. M., BODEY G. P., NIES B. A., FREIREICH E. J. CAUSES OF DEATH IN ACUTE LEUKEMIA: A TEN-YEAR STUDY OF 414 PATIENTS FROM 1954-1963. JAMA. 1965 Jul 12;193:105–109. doi: 10.1001/jama.1965.03090020019005. [DOI] [PubMed] [Google Scholar]
  10. Keating M. J., Penington D. G. Prophylaxis against septicaemia in acute leukaemia: the use of oral framycetin. Med J Aust. 1973 Aug 4;2(5):213–217. [PubMed] [Google Scholar]
  11. Klastersky J., Debusscher L., Weerts D., Daneau D. Use of oral antibiotics in protected units environment: clinical effectiveness and role in the emergence of antibiotic-resistant strains. Pathol Biol (Paris) 1974 Jan;22(1):5–12. [PubMed] [Google Scholar]
  12. Levi J. A., Vincent P. C., Jennis F., Lind D. E., Gunz F. W. Prophylactic oral antibiotics in the management of acute leukaemia. Med J Aust. 1973 May 26;1(21):1025–1029. [PubMed] [Google Scholar]
  13. Levine A. S., Robinson R. A., Hauser J. M. Analysis of studies on protected environments and prophylactic antibiotics in adult acute leukemia. Eur J Cancer. 1975 Aug;11SUPPL:57–66. doi: 10.1016/b978-0-08-019964-1.50011-7. [DOI] [PubMed] [Google Scholar]
  14. Levine A. S., Schimpff S. C., Graw R. G., Jr, Young R. C. Hematologic malignancies and other marrow failure states: progress in the management of complicating infections. Semin Hematol. 1974 Apr;11(2):141–202. [PubMed] [Google Scholar]
  15. Levine A. S., Siegel S. E., Schreiber A. D., Hauser J., Preisler H., Goldstein I. M., Seidler F., Simon R., Perry S., Bennett J. E. Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia. N Engl J Med. 1973 Mar 8;288(10):477–483. doi: 10.1056/NEJM197303082881001. [DOI] [PubMed] [Google Scholar]
  16. Pizzo P. A., Levine A. S. The utility of protected-environment regimens for the compromised host: a critical assessment. Prog Hematol. 1977;10:311–332. [PubMed] [Google Scholar]
  17. Preisler H. D., Goldstein I. M., Henderson E. S. Gastrointestinal "sterilization" in the treatment of patients with acute leukemia. Cancer. 1970 Nov;26(5):1076–1081. doi: 10.1002/1097-0142(197011)26:5<1076::aid-cncr2820260516>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  18. Schimpff S. C., Greene W. H., Young V. M., Fortner C. L., Cusack N., Block J. B., Wiernik P. H. Infection prevention in acute nonlymphocytic leukemia. Laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Intern Med. 1975 Mar;82(3):351–358. doi: 10.7326/0003-4819-82-3-351. [DOI] [PubMed] [Google Scholar]
  19. Schimpff S. C., Young V. M., Greene W. H., Vermeulen G. D., Moody M. R., Wiernik P. H. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med. 1972 Nov;77(5):707–714. doi: 10.7326/0003-4819-77-5-707. [DOI] [PubMed] [Google Scholar]
  20. Schimpff S., Satterlee W., Young V. M., Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971 May 13;284(19):1061–1065. doi: 10.1056/NEJM197105132841904. [DOI] [PubMed] [Google Scholar]
  21. Storring R. A., Jameson B., McElwain T. J., Wiltshaw E. Oral non-absorbed antibiotics prevent infection in acute non-lymphoblastic leukaemia. Lancet. 1977 Oct 22;2(8043):837–840. doi: 10.1016/s0140-6736(77)90779-6. [DOI] [PubMed] [Google Scholar]
  22. Wiernik P. H., Schimpff S. C., Schiffer C. A., Lichtenfeld J. L., Aisner J., O'Connell M. J., Fortner C. Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia. Cancer Treat Rep. 1976 Jan;60(1):41–53. [PubMed] [Google Scholar]
  23. Yates J. W., Holland J. F. A controlled study of isolation and endogenous microbial suppression in acute myelocytic leukemia patients. Cancer. 1973 Dec;32(6):1490–1498. doi: 10.1002/1097-0142(197312)32:6<1490::aid-cncr2820320628>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES